[go: up one dir, main page]

PE20211585A1 - Agente profilactico o terapeutico para atrofia muscular espinal - Google Patents

Agente profilactico o terapeutico para atrofia muscular espinal

Info

Publication number
PE20211585A1
PE20211585A1 PE2020002186A PE2020002186A PE20211585A1 PE 20211585 A1 PE20211585 A1 PE 20211585A1 PE 2020002186 A PE2020002186 A PE 2020002186A PE 2020002186 A PE2020002186 A PE 2020002186A PE 20211585 A1 PE20211585 A1 PE 20211585A1
Authority
PE
Peru
Prior art keywords
aliphatic heterocycle
optionally substituted
muscular atrophy
spinal muscular
hydrogen atom
Prior art date
Application number
PE2020002186A
Other languages
English (en)
Inventor
Koji Fuji
Takeshi Yamasaki
Shunya Suzuki
Koji Ono
Hiroki TAKAHAGI
Original Assignee
Reborna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reborna Biosciences Inc filed Critical Reborna Biosciences Inc
Publication of PE20211585A1 publication Critical patent/PE20211585A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
    • A61C8/0093—Features of implants not otherwise provided for
    • A61C8/0096—Implants for use in orthodontic treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)

Abstract

La presente invencion se refiere a compuestos representados por la formula 1 o una sal de estos, en donde: W1, W2 y W3 se seleccionan cada uno independientemente del grupo que consiste en C-R2, C-R3, C-Rc y C-Rd, y se definen mediante uno de los siguientes (i) a (iv): (i) cuando W3 es C-R2, entonces W1 es C-R3, W2 es C-Rc o N, y R1 es un atomo de hidrogeno; (ii) cuando W3 es C-R3, entonces W1 es C-R2, W2 es C-Rc o N, y R1 es un atomo de hidrogeno, alquilo C1-8 o alcoxi C1-8; (iii) cuando W1 es C-R2, entonces W2 es C-Rc o N, W3 es C-Rd, y R1 es un heterociclo alifatico que contiene uno o mas atomos de nitrogeno, donde el heterociclo alifatico se sustituye opcionalmente con un sustituyente no aromatico; y (iv) cuando W2 es C-R2, W1 es C-Rc, W3 es C-Rd, y R1 es un heterociclo alifatico que contiene uno o mas atomos de nitrogeno, donde el heterociclo alifatico se sustituye opcionalmente con un sustituyente no aromatico; R2 es un anillo aromatico de 6 o mas miembros opcionalmente sustituido con un sustituyente no aromatico; R3 es un heterociclo alifatico que contiene uno o mas atomos de nitrogeno, donde el heterociclo alifatico se sustituye opcionalmente con un sustituyente no aromatico; Q1 se selecciona de C-Ra y N; Q2 se selecciona de C-Rb y N; y Ra, Rb, Rc y Rd se seleccionan cada uno independientemente del grupo que consiste en un atomo de hidrogeno, halogeno, alquilo C1-8, alcoxi C1-8 y un grupo ciano. Son compuestos preferidos: (S)-6-(2,4-dimetilpiperazin-1-il)-2-(4,6-dimetilpirazolo[1,5-a]pirazin-2-il)quinazolin-4(3H)-ona; 2-(4,6-dimetilpirazolo[1,5-a]pirazin-2-il)-6-(4-metilpiperazin-1-il)quinazolin-4(3H)-ona, entre otros. Tambien se refiere a un medicamento, un regulador de empalme, un potenciador de expresion del ARNm de SMN con funcion normal y/o proteina SMN de funcion normal, un agente profilactico de atrofia muscular espinal (SMA) asociados al compuesto de la invencion. Los compuestos de la invencion tienen utilidad como agentes profilacticos o terapeuticos para la atrofia muscular espinal, potenciando la expresion del ARNm normal del gen de supervivencia de motoneuronas 1 (SMN1) o su proteina funcional.
PE2020002186A 2018-06-27 2019-06-27 Agente profilactico o terapeutico para atrofia muscular espinal PE20211585A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018122551 2018-06-27
PCT/JP2019/025732 WO2020004594A1 (ja) 2018-06-27 2019-06-27 脊髄性筋萎縮症の予防または治療剤

Publications (1)

Publication Number Publication Date
PE20211585A1 true PE20211585A1 (es) 2021-08-18

Family

ID=68986733

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020002186A PE20211585A1 (es) 2018-06-27 2019-06-27 Agente profilactico o terapeutico para atrofia muscular espinal

Country Status (22)

Country Link
US (1) US12012410B2 (es)
EP (1) EP3816160A4 (es)
JP (1) JP7427252B2 (es)
KR (1) KR102693282B1 (es)
CN (1) CN112469707B (es)
AU (2) AU2019293757B2 (es)
BR (1) BR112020026637A2 (es)
CA (1) CA3105174A1 (es)
CL (1) CL2020003386A1 (es)
CO (1) CO2021000808A2 (es)
CR (1) CR20210050A (es)
EA (1) EA202190116A1 (es)
IL (1) IL279786B2 (es)
JO (1) JOP20200338A1 (es)
MX (1) MX2020014116A (es)
MY (1) MY203060A (es)
PE (1) PE20211585A1 (es)
PH (1) PH12020552263A1 (es)
SG (1) SG11202013088YA (es)
UA (1) UA128696C2 (es)
WO (1) WO2020004594A1 (es)
ZA (1) ZA202100556B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2579747B8 (en) 2017-08-04 2022-10-05 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
FI3814348T3 (fi) 2018-06-27 2023-09-22 Bristol Myers Squibb Co Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina
BR112021001131A2 (pt) * 2018-07-26 2021-04-20 Domain Therapeutics derivados de quinazolinona substituídos e seu uso como moduladores alostéricos positivos de mglur4
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR20220159386A (ko) * 2020-02-28 2022-12-02 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
AU2021253571A1 (en) * 2020-04-08 2022-11-10 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20230159496A1 (en) * 2020-04-08 2023-05-25 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240002375A1 (en) * 2020-07-02 2024-01-04 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the tre
CN117015536A (zh) * 2020-07-02 2023-11-07 雷密克斯医疗公司 作为核酸剪接和增殖性疾病治疗的调节剂的2-(吲唑-5-基)-6-(哌啶-4-基)-1,7-萘啶衍生物及相关化合物
TW202216725A (zh) 2020-07-02 2022-05-01 美商雷密克斯醫療公司 調控剪接之化合物及方法
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
US20240366612A1 (en) * 2021-10-13 2024-11-07 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
AU2022365100A1 (en) * 2021-10-13 2024-05-02 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023133217A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2023133225A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023133229A2 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1050750B (it) 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
US6566367B2 (en) 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
WO2010019236A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Methods for treating spinal muscular atrophy
CN115227710A (zh) 2009-06-17 2022-10-25 冷泉港实验室 用于在对象中调节smn2剪接的组合物和方法
PE20170003A1 (es) * 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
EP2488520B1 (en) * 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
EP2678018A4 (en) * 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
US8710064B2 (en) * 2011-10-20 2014-04-29 China Medical University 2-aryl-4-quinazolinones and their pharmaceutical compositions
JP6126615B2 (ja) * 2011-11-11 2017-05-10 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
EA029984B1 (ru) 2011-12-30 2018-06-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
WO2013112788A1 (en) 2012-01-26 2013-08-01 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
SG11201404713PA (en) 2012-02-10 2014-09-26 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
MX352962B (es) 2012-03-01 2017-12-15 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal.
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
WO2014093869A1 (en) 2012-12-13 2014-06-19 University Of Kansas 6-substituted quinazolinone inhibitors
US20160089371A1 (en) 2013-03-15 2016-03-31 Intellikine, Llc Combination of Kinase Inhibitors and Uses Thereof
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
MX363456B (es) 2013-06-25 2019-03-25 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal.
KR20160045063A (ko) 2013-08-19 2016-04-26 에프. 호프만-라 로슈 아게 스크리닝 방법
WO2015095446A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
CR20160518A (es) 2014-05-15 2017-02-21 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
MX375925B (es) 2014-06-25 2025-03-07 Hoffmann La Roche Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
JP6869947B2 (ja) 2015-07-22 2021-05-12 アラクセス ファーマ エルエルシー 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用
CN108026046B (zh) * 2015-07-22 2021-12-21 亚瑞克西斯制药公司 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途
EP4360707A3 (en) * 2015-11-12 2024-08-07 F. Hoffmann-La Roche AG Compositions for treating spinal muscular atrophy
WO2018140514A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
JP6868410B2 (ja) 2017-02-03 2021-05-12 エスアイアイ・プリンテック株式会社 液体噴射ヘッドチップ、液体噴射ヘッドおよび液体噴射装置

Also Published As

Publication number Publication date
ZA202100556B (en) 2024-09-25
AU2019293757B2 (en) 2022-09-15
IL279786B1 (en) 2024-10-01
WO2020004594A1 (ja) 2020-01-02
NZ772352A (en) 2024-05-31
MX2020014116A (es) 2021-06-15
EP3816160A1 (en) 2021-05-05
UA128696C2 (uk) 2024-10-02
CA3105174A1 (en) 2020-01-02
CN112469707A (zh) 2021-03-09
KR20210025625A (ko) 2021-03-09
JP7427252B2 (ja) 2024-02-05
US12012410B2 (en) 2024-06-18
CN112469707B (zh) 2024-06-21
EP3816160A4 (en) 2022-03-16
CL2020003386A1 (es) 2021-05-14
IL279786A (en) 2021-03-01
CR20210050A (es) 2021-06-10
AU2022283732A1 (en) 2023-02-02
JPWO2020004594A1 (ja) 2021-07-15
KR102693282B1 (ko) 2024-08-12
AU2019293757A1 (en) 2021-02-04
JOP20200338A1 (ar) 2020-12-24
BR112020026637A2 (pt) 2021-03-30
IL279786B2 (en) 2025-02-01
EA202190116A1 (ru) 2021-08-30
SG11202013088YA (en) 2021-02-25
US20220287748A1 (en) 2022-09-15
PH12020552263A1 (en) 2021-06-28
MY203060A (en) 2024-06-06
CO2021000808A2 (es) 2021-04-30

Similar Documents

Publication Publication Date Title
PE20211585A1 (es) Agente profilactico o terapeutico para atrofia muscular espinal
PE20211411A1 (es) Compuestos de anillo fusionado
PE20070021A1 (es) Compuestos triazolopiridinas como antagonistas de receptor canabinoide 1
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
ES2676180T3 (es) Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20230827A1 (es) [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2
PE20210129A1 (es) Compuestos de 4-azaindol
PE20240239A1 (es) Compuestos heterociclicos
BR112022005674A2 (pt) Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo
UY28157A1 (es) Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos
PE20230679A1 (es) Inhibidores heterociclicos de pad4
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
PE20090054A1 (es) Derivados de purina
BRPI0507945A (pt) derivados de azabiciclo (3.1.0) hexano utilizáveis como moduladores de receptores d3 de dopamina
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
PE20211388A1 (es) Compuestos
SI2981533T1 (en) Protein Protein Kinase
PE20140381A1 (es) Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
UY29316A1 (es) Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos.
PE20212325A1 (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb
AR065531A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.
UY29301A1 (es) Derivados amida
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos